Peregrine Capital Management LLC Sells 123,337 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Peregrine Capital Management LLC lowered its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 16.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 605,348 shares of the biopharmaceutical company's stock after selling 123,337 shares during the quarter. Peregrine Capital Management LLC owned 0.21% of Amicus Therapeutics worth $8,590,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the company. Envestnet Asset Management Inc. boosted its holdings in shares of Amicus Therapeutics by 170.6% during the 3rd quarter. Envestnet Asset Management Inc. now owns 393,728 shares of the biopharmaceutical company's stock worth $4,788,000 after buying an additional 248,220 shares during the period. O Shaughnessy Asset Management LLC raised its stake in Amicus Therapeutics by 25.3% during the 3rd quarter. O Shaughnessy Asset Management LLC now owns 15,243 shares of the biopharmaceutical company's stock valued at $185,000 after purchasing an additional 3,082 shares during the last quarter. Vanguard Group Inc. raised its stake in Amicus Therapeutics by 0.4% during the 3rd quarter. Vanguard Group Inc. now owns 27,131,873 shares of the biopharmaceutical company's stock valued at $329,924,000 after purchasing an additional 107,456 shares during the last quarter. MPM Bioimpact LLC raised its stake in Amicus Therapeutics by 38.7% during the 3rd quarter. MPM Bioimpact LLC now owns 716,139 shares of the biopharmaceutical company's stock valued at $8,708,000 after purchasing an additional 200,000 shares during the last quarter. Finally, Fiera Capital Corp raised its stake in Amicus Therapeutics by 2.1% during the 3rd quarter. Fiera Capital Corp now owns 5,085,871 shares of the biopharmaceutical company's stock valued at $61,844,000 after purchasing an additional 106,086 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several research firms recently commented on FOLD. Cantor Fitzgerald reiterated an "overweight" rating and set a $22.00 target price on shares of Amicus Therapeutics in a research note on Thursday, February 29th. JPMorgan Chase & Co. cut their target price on shares of Amicus Therapeutics from $21.00 to $19.00 and set an "overweight" rating for the company in a research note on Monday, March 18th. Finally, Morgan Stanley upgraded shares of Amicus Therapeutics from an "equal weight" rating to an "overweight" rating and upped their target price for the company from $15.00 to $20.00 in a research note on Tuesday, December 19th.

Amicus Therapeutics Price Performance

Shares of FOLD stock traded down $0.48 during mid-day trading on Wednesday, reaching $11.27. The company's stock had a trading volume of 2,453,488 shares, compared to its average volume of 3,064,803. Amicus Therapeutics, Inc. has a 1-year low of $9.70 and a 1-year high of $14.57. The company has a market cap of $3.33 billion, a P/E ratio of -22.10 and a beta of 0.75. The company has a debt-to-equity ratio of 2.42, a quick ratio of 2.52 and a current ratio of 2.88. The firm's 50-day moving average is $12.50 and its two-hundred day moving average is $12.07.

Amicus Therapeutics (NASDAQ:FOLD - Get Free Report) last announced its quarterly earnings data on Wednesday, February 28th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.05). Amicus Therapeutics had a negative net margin of 37.96% and a negative return on equity of 119.46%. The business had revenue of $115.08 million during the quarter, compared to analyst estimates of $115.11 million. On average, research analysts predict that Amicus Therapeutics, Inc. will post 0.02 earnings per share for the current year.

Insider Activity

In related news, CEO Bradley L. Campbell sold 4,167 shares of the stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $14.00, for a total transaction of $58,338.00. Following the completion of the sale, the chief executive officer now owns 871,219 shares in the company, valued at approximately $12,197,066. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, CEO Bradley L. Campbell sold 4,167 shares of the stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $14.00, for a total transaction of $58,338.00. Following the completion of the sale, the chief executive officer now owns 871,219 shares in the company, valued at approximately $12,197,066. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Margaret G. Mcglynn sold 7,500 shares of the stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $13.40, for a total transaction of $100,500.00. Following the sale, the director now owns 59,289 shares of the company's stock, valued at approximately $794,472.60. The disclosure for this sale can be found here. In the last 90 days, insiders sold 135,049 shares of company stock worth $1,750,474. 2.10% of the stock is currently owned by corporate insiders.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.